Identification

Name
Pargyline
Accession Number
DB01626
Type
Small Molecule
Groups
Approved
Description

A monoamine oxidase inhibitor with antihypertensive properties. [PubChem]

Structure
Thumb
Synonyms
  • Eutonyl
  • Eutron
  • Pargyline
External IDs
Lopac-P-8013
Product Ingredients
IngredientUNIICASInChI Key
Pargyline hydrochlorideW70V6I2OMY306-07-0BCXCABRDBBWWGY-UHFFFAOYSA-N
International/Other Brands
Eutonyl
Categories
UNII
9MV14S8G3E
CAS number
555-57-7
Weight
Average: 159.2276
Monoisotopic: 159.104799421
Chemical Formula
C11H13N
InChI Key
DPWPWRLQFGFJFI-UHFFFAOYSA-N
InChI
InChI=1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3
IUPAC Name
benzyl(methyl)(prop-2-yn-1-yl)amine
SMILES
CN(CC#C)CC1=CC=CC=C1

Pharmacology

Indication

For the treatment of moderate to severe hypertension.

Structured Indications
Not Available
Pharmacodynamics

Pargyline is a monoamine oxidase B (MAO-B) inhibitor with antihypertensive properties. Patients taking pargyline must avoid concurrent consumption of tyramine-containing foods such as bleu cheese and beer, as this can lead to a hypertensive crisis.

Mechanism of action

MAOIs act by inhibiting the activity of monoamine oxidase, thus preventing the breakdown of monoamine neurotransmitters and thereby increasing their availability. There are two isoforms of monoamine oxidase, MAO-A and MAO-B. MAO-A preferentially deaminates serotonin, melatonin, epinephrine and norepinephrine. MAO-B preferentially deaminates phenylethylamine and trace amines. Pargyline functions by inhibiting the metabolism of catecholamines and tyramine within presynaptic nerve terminals. Catecholamines cause general physiological changes that prepare the body for physical activity (fight-or-flight response). Some typical effects are increases in heart rate, blood pressure, blood glucose levels, and a general reaction of the sympathetic nervous system.

TargetActionsOrganism
AAmine oxidase [flavin-containing] B
inhibitor
Human
UAmine oxidase [flavin-containing] A
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetaminePargyline may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetaminePargyline may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePargyline may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Pargyline.Experimental
AcarbosePargyline may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololPargyline may increase the hypotensive activities of Acebutolol.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Pargyline.Experimental
AlbiglutidePargyline may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Pargyline.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Pargyline.Approved, Investigational
AliskirenPargyline may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Pargyline.Approved, Investigational
AlogliptinPargyline may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Pargyline.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Pargyline.Illicit
AlprenololPargyline may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Pargyline.Approved
AmbrisentanPargyline may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostinePargyline may increase the hypotensive activities of Amifostine.Approved, Investigational
AmineptinePargyline may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylinePargyline may increase the serotonergic activities of Amitriptyline.Approved
AmlodipinePargyline may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Pargyline is combined with Amoxapine.Approved
AmphetaminePargyline may increase the hypertensive activities of Amphetamine.Approved, Illicit
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Pargyline.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Pargyline is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Pargyline is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Arformoterol.Approved, Investigational
AtenololPargyline may increase the hypotensive activities of Atenolol.Approved
AtomoxetinePargyline may increase the central neurotoxic activities of Atomoxetine.Approved
AtropinePargyline may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Bambuterol.Approved, Investigational
BenazeprilPargyline may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazidePargyline may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Pargyline.Withdrawn
BenzphetaminePargyline may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilPargyline may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Pargyline.Approved
BetaxololPargyline may increase the hypotensive activities of Betaxolol.Approved
BethanidinePargyline may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Pargyline is combined with Bezafibrate.Approved
BietaserpinePargyline may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostPargyline may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololPargyline may increase the hypotensive activities of Bisoprolol.Approved
BosentanPargyline may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Pargyline may increase the hypotensive activities of BQ-123.Investigational
BretyliumPargyline may increase the hypotensive activities of Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Pargyline is combined with Brimonidine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Pargyline.Experimental
BromocriptinePargyline may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BupranololPargyline may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pargyline.Approved, Illicit, Investigational, Vet Approved
BupropionPargyline may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pargyline.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pargyline.Approved, Illicit, Vet Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Pargyline.Approved
CadralazinePargyline may increase the hypotensive activities of Cadralazine.Experimental
CafedrinePargyline may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinPargyline may increase the hypoglycemic activities of Canagliflozin.Approved
Candesartan cilexetilPargyline may increase the hypotensive activities of Candesartan.Approved
CandoxatrilPargyline may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilPargyline may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pargyline.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Pargyline.Illicit, Investigational, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Pargyline.Withdrawn
CarteololPargyline may increase the hypotensive activities of Carteolol.Approved
CarvedilolPargyline may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololPargyline may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazidePargyline may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenterminePargyline may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpropamidePargyline may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidonePargyline may increase the hypotensive activities of Chlorthalidone.Approved
CicletaninePargyline may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilPargyline may increase the hypotensive activities of Cilazapril.Approved
CirazolinePargyline may increase the hypertensive activities of Cirazoline.Experimental
CitalopramPargyline may increase the serotonergic activities of Citalopram.Approved
ClemastinePargyline may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipraminePargyline may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonidinePargyline may increase the hypotensive activities of Clonidine.Approved
CloranololPargyline may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pargyline.Approved, Illicit
CryptenaminePargyline may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Pargyline.Approved
CyclopenthiazidePargyline may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazidePargyline may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadinePargyline may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinPargyline may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetinePargyline may increase the serotonergic activities of Dapoxetine.Investigational
DebrisoquinPargyline may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilPargyline may increase the hypotensive activities of Delapril.Experimental
DeserpidinePargyline may increase the hypotensive activities of Deserpidine.Approved
DesipraminePargyline may increase the serotonergic activities of Desipramine.Approved
DesvenlafaxinePargyline may increase the serotonergic activities of Desvenlafaxine.Approved
DexmethylphenidatePargyline may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetaminePargyline may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanPargyline may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pargyline.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pargyline.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Pargyline.Approved, Investigational
DiazoxideDiazoxide may increase the hypotensive activities of Pargyline.Approved
DibenzepinPargyline may increase the serotonergic activities of Dibenzepin.Experimental
diethylnorsperminePargyline may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionPargyline may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazinePargyline may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pargyline.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Pargyline.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pargyline.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pargyline.Experimental, Illicit
DiltiazemPargyline may increase the hypotensive activities of Diltiazem.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pargyline.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Pargyline is combined with Dipivefrin.Approved
DisopyramidePargyline may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Pargyline is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamidePargyline may increase the hypotensive activities of Dorzolamide.Approved
DosulepinPargyline may increase the serotonergic activities of Dosulepin.Approved
DoxapramPargyline may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinPargyline may increase the hypotensive activities of Doxazosin.Approved
DoxepinPargyline may increase the serotonergic activities of Doxepin.Approved
DoxylaminePargyline may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Pargyline.Investigational
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Pargyline.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Pargyline is combined with Droxidopa.Approved, Investigational
DulaglutidePargyline may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetinePargyline may increase the serotonergic activities of Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Pargyline.Experimental, Illicit
EfonidipinePargyline may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Pargyline.Approved, Investigational
EmpagliflozinPargyline may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilPargyline may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatPargyline may increase the hypotensive activities of Enalaprilat.Approved
EndralazinePargyline may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Pargyline.Approved, Investigational
EpanololPargyline may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Pargyline is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpoprostenolPargyline may increase the hypotensive activities of Epoprostenol.Approved
EprosartanPargyline may increase the hypotensive activities of Eprosartan.Approved
ErgotaminePargyline may increase the hypertensive activities of Ergotamine.Approved
EscitalopramPargyline may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapinePargyline may increase the serotonergic activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Pargyline.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pargyline.Approved, Illicit
EtoperidonePargyline may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Pargyline.Illicit, Vet Approved
ExenatidePargyline may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipinePargyline may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineThe risk or severity of adverse effects can be increased when Pargyline is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FenoldopamPargyline may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Fenoterol.Approved, Investigational
FentanylFentanyl may increase the serotonergic activities of Pargyline.Approved, Illicit, Investigational, Vet Approved
Ferulic acidPargyline may increase the hypotensive activities of Ferulic acid.Experimental
FluoxetinePargyline may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FluvoxaminePargyline may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Formoterol.Approved, Investigational
FosinoprilPargyline may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Pargyline.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Pargyline.Approved, Investigational, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Pargyline.Experimental
GliclazidePargyline may increase the hypoglycemic activities of Gliclazide.Approved
GlimepiridePargyline may increase the hypoglycemic activities of Glimepiride.Approved
GlipizidePargyline may increase the hypoglycemic activities of Glipizide.Approved
GlyburidePargyline may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzPargyline may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelPargyline may increase the hypotensive activities of Guanadrel.Approved
GuanazodinePargyline may increase the hypotensive activities of Guanazodine.Experimental
GuanethidinePargyline may increase the hypotensive activities of Guanethidine.Approved
GuanfacinePargyline may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorPargyline may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzPargyline may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanPargyline may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Pargyline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Pargyline.Approved, Illicit, Investigational
HexamethoniumPargyline may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineHydracarbazine may increase the hypotensive activities of Pargyline.Experimental
HydralazinePargyline may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazidePargyline may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Hydrocodone.Approved, Illicit
HydroflumethiazidePargyline may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Hydromorphone.Approved, Illicit
HydroxyamphetaminePargyline may increase the hypertensive activities of Hydroxyamphetamine.Approved
IloprostIloprost may increase the hypotensive activities of Pargyline.Approved, Investigational
ImidaprilPargyline may increase the hypotensive activities of Imidapril.Investigational
ImipraminePargyline may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Indacaterol.Approved
IndalpinePargyline may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamidePargyline may increase the hypotensive activities of Indapamide.Approved
IndenololPargyline may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminPargyline may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartPargyline may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirPargyline may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlarginePargyline may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisinePargyline may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanPargyline may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproPargyline may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Pargyline.Approved
IprindolePargyline may increase the serotonergic activities of Iprindole.Experimental
IproclozideIproclozide may increase the hypotensive activities of Pargyline.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Pargyline.Withdrawn
IrbesartanPargyline may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Pargyline.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Pargyline is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Pargyline is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Pargyline is combined with Isoprenaline.Approved
IsradipinePargyline may increase the hypotensive activities of Isradipine.Approved
KetanserinPargyline may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pargyline.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Pargyline.Approved, Nutraceutical, Withdrawn
LabetalolPargyline may increase the hypotensive activities of Labetalol.Approved
LacidipinePargyline may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostPargyline may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipinePargyline may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Pargyline.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pargyline.Approved, Investigational
LevomilnacipranPargyline may increase the serotonergic activities of Levomilnacipran.Approved
LevonordefrinPargyline may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pargyline.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Pargyline is combined with Levosalbutamol.Approved
LinezolidThe risk or severity of adverse effects can be increased when Pargyline is combined with Linezolid.Approved, Investigational
LinsidominePargyline may increase the hypotensive activities of Linsidomine.Experimental
LiraglutidePargyline may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetaminePargyline may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilPargyline may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Pargyline.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Pargyline is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Pargyline.Illicit
LofepraminePargyline may increase the serotonergic activities of Lofepramine.Experimental
LofexidinePargyline may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanPargyline may increase the hypotensive activities of Losartan.Approved
MacitentanPargyline may increase the hypotensive activities of Macitentan.Approved
ManidipinePargyline may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pargyline.Approved
MebanazineMebanazine may increase the hypotensive activities of Pargyline.Withdrawn
MecamylaminePargyline may increase the hypotensive activities of Mecamylamine.Approved
MecaserminPargyline may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MephedronePargyline may increase the hypertensive activities of Mephedrone.Investigational
MephenterminePargyline may increase the hypertensive activities of Mephentermine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Pargyline.Experimental
MequitazinePargyline may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolPargyline may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminPargyline may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Pargyline.Approved, Illicit
MethamphetaminePargyline may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethoserpidinePargyline may increase the hypotensive activities of Methoserpidine.Experimental
MethoxaminePargyline may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Pargyline.Experimental
MethyldopaThe risk or severity of adverse effects can be increased when Pargyline is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Pargyline.Experimental
Methylene bluePargyline may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Pargyline.Approved, Investigational
MetipranololPargyline may increase the hypotensive activities of Metipranolol.Approved
MetolazonePargyline may increase the hypotensive activities of Metolazone.Approved
MetoprololPargyline may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosinePargyline may increase the hypotensive activities of Metyrosine.Approved
MianserinPargyline may increase the neurotoxic activities of Mianserin.Approved, Investigational
MibefradilPargyline may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrinePargyline may increase the hypertensive activities of Midodrine.Approved
MidomafetaminePargyline may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit, Investigational
MifepristonePargyline may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolPargyline may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranPargyline may increase the serotonergic activities of Milnacipran.Approved
MinaprineMinaprine may increase the hypotensive activities of Pargyline.Approved
MinoxidilPargyline may increase the hypotensive activities of Minoxidil.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Pargyline.Investigational
MirtazapinePargyline may increase the central neurotoxic activities of Mirtazapine.Approved
MMDAPargyline may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Pargyline is combined with Moclobemide.Approved
MoexiprilPargyline may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Pargyline.Approved, Investigational
MoxonidinePargyline may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzoliminePargyline may increase the hypotensive activities of Muzolimine.Experimental
NadololPargyline may increase the hypotensive activities of Nadolol.Approved
NaftopidilPargyline may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pargyline.Approved
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Pargyline.Approved, Investigational
NateglinidePargyline may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololPargyline may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodonePargyline may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the hypotensive activities of Pargyline.Withdrawn
NicardipinePargyline may increase the hypotensive activities of Nicardipine.Approved
NicorandilPargyline may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipinePargyline may increase the hypotensive activities of Niguldipine.Experimental
NilvadipinePargyline may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipinePargyline may increase the hypotensive activities of Nimodipine.Approved
NisoldipinePargyline may increase the hypotensive activities of Nisoldipine.Approved
NitrendipinePargyline may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussidePargyline may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrinePargyline may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Pargyline.Approved, Illicit
NortriptylinePargyline may increase the serotonergic activities of Nortriptyline.Approved
ObinutuzumabPargyline may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Pargyline.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Pargyline is combined with Olanzapine.Approved, Investigational
OlmesartanPargyline may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Olodaterol.Approved
OmapatrilatPargyline may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolPargyline may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Pargyline.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Pargyline is combined with Orciprenaline.Approved
OxprenololPargyline may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pargyline.Approved, Investigational, Vet Approved
ParoxetinePargyline may increase the serotonergic activities of Paroxetine.Approved, Investigational
PenbutololPargyline may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidinePargyline may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pargyline.Approved, Vet Approved
PentoliniumPargyline may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Pargyline.Approved, Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Pargyline.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPargyline may increase the hypotensive activities of Perindopril.Approved
PethidinePargyline may increase the serotonergic activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Pargyline.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Pargyline.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Pargyline.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Pargyline.Experimental
PhenoxybenzaminePargyline may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Pargyline.Withdrawn
PhenterminePargyline may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolaminePargyline may increase the hypotensive activities of Phentolamine.Approved
PhenylephrinePargyline may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Pargyline is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Pargyline.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Pargyline.Investigational
PinacidilPargyline may increase the hypotensive activities of Pinacidil.Withdrawn
PindololPargyline may increase the hypotensive activities of Pindolol.Approved
PioglitazonePargyline may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Pargyline.Investigational
PirlindolePirlindole may increase the hypotensive activities of Pargyline.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Pargyline.Withdrawn
PizotifenPargyline may increase the anticholinergic activities of Pizotifen.Approved
PolythiazidePargyline may increase the hypotensive activities of Polythiazide.Approved
PramlintidePargyline may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinPargyline may increase the hypotensive activities of Prazosin.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Procaterol.Approved, Investigational
PropranololPargyline may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylinePargyline may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Pargyline.Investigational
PseudoephedrinePargyline may increase the hypertensive activities of Pseudoephedrine.Approved
QuinaprilPargyline may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Pargyline.Approved
RamiprilPargyline may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Pargyline.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Pargyline.Approved
RemikirenPargyline may increase the hypotensive activities of Remikiren.Approved
RepaglinidePargyline may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnaminePargyline may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Pargyline is combined with Reserpine.Approved, Investigational
RilmenidinePargyline may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatPargyline may increase the hypotensive activities of Riociguat.Approved
RitobegronPargyline may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Pargyline is combined with Ritodrine.Approved, Investigational
RituximabPargyline may increase the hypotensive activities of Rituximab.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Pargyline.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Pargyline.Approved, Investigational
RosiglitazonePargyline may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Pargyline.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Pargyline is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Salmeterol.Approved
SaprisartanPargyline may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinPargyline may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypotensive activities of Pargyline.Approved, Investigational, Vet Approved
SelexipagPargyline may increase the hypotensive activities of Selexipag.Approved
SertralinePargyline may increase the serotonergic activities of Sertraline.Approved
SildenafilSildenafil may increase the antihypertensive activities of Pargyline.Approved, Investigational
SitagliptinPargyline may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanPargyline may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilPargyline may increase the hypotensive activities of Spirapril.Approved
SufentanilSufentanil may increase the serotonergic activities of Pargyline.Approved, Investigational
SulfadiazinePargyline may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazolePargyline may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazolePargyline may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Pargyline.Approved, Investigational
SunitinibPargyline may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Pargyline.Approved, Investigational
TalinololPargyline may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pargyline.Approved
TelmisartanPargyline may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilPargyline may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Pargyline is combined with Terbutaline.Approved
TerlipressinPargyline may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Pargyline.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pargyline.Approved
TetrahydropalmatinePargyline may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolinePargyline may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalinePargyline may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Pargyline.Approved, Investigational
TibolonePargyline may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenPargyline may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Pargyline.Experimental
TimololPargyline may increase the hypotensive activities of Timolol.Approved
TolazamidePargyline may increase the hypoglycemic activities of Tolazamide.Approved
TolazolinePargyline may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamidePargyline may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pargyline.Approved, Withdrawn
TolonidinePargyline may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Pargyline.Approved
TorasemidePargyline may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Pargyline.Approved, Investigational
TrandolaprilPargyline may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Pargyline.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Pargyline.Approved
TravoprostPargyline may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Trazodone.Approved, Investigational
TreprostinilPargyline may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazidePargyline may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinPargyline may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanPargyline may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipraminePargyline may increase the serotonergic activities of Trimipramine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Pargyline.Approved, Investigational
UnoprostonePargyline may increase the hypotensive activities of Unoprostone.Approved
UrapidilPargyline may increase the hypotensive activities of Urapidil.Investigational
ValsartanPargyline may increase the hypotensive activities of Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Pargyline.Approved
VenlafaxinePargyline may increase the serotonergic activities of Venlafaxine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Pargyline.Approved
VincaminePargyline may increase the hypotensive activities of Vincamine.Experimental
VinpocetinePargyline may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Pargyline.Approved
XipamidePargyline may increase the hypotensive activities of Xipamide.Experimental
XylometazolinePargyline may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Pargyline.Approved, Vet Approved
ZimelidinePargyline may increase the serotonergic activities of Zimelidine.Withdrawn
ZofenoprilPargyline may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Pargyline.Approved, Investigational
Food Interactions
  • Food increases the oral bioavailability by 3-5 fold.

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15563
KEGG Compound
C07414
PubChem Compound
4688
PubChem Substance
46507368
ChemSpider
4526
BindingDB
50172756
ChEBI
7930
ChEMBL
CHEMBL673
Therapeutic Targets Database
DAP000580
PharmGKB
PA450797
Wikipedia
Pargyline
ATC Codes
C02LL01 — Pargyline and diureticsC02KC01 — Pargyline

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0998 mg/mLALOGPS
logP2.05ALOGPS
logP2.14ChemAxon
logS-3.2ALOGPS
pKa (Strongest Basic)8.13ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity52.18 m3·mol-1ChemAxon
Polarizability18.78 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9504
Blood Brain Barrier+0.9568
Caco-2 permeable+0.8188
P-glycoprotein substrateNon-substrate0.6641
P-glycoprotein inhibitor INon-inhibitor0.9864
P-glycoprotein inhibitor IINon-inhibitor0.9357
Renal organic cation transporterNon-inhibitor0.5518
CYP450 2C9 substrateNon-substrate0.8061
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6977
CYP450 1A2 substrateNon-inhibitor0.7981
CYP450 2C9 inhibitorNon-inhibitor0.9213
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.945
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7826
Ames testNon AMES toxic0.9413
CarcinogenicityNon-carcinogens0.5475
BiodegradationNot ready biodegradable0.9459
Rat acute toxicity2.6935 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7258
hERG inhibition (predictor II)Non-inhibitor0.8819
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (10 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9200000000-48da979999f0c1f29bef
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9200000000-ab18807e68b6d65f5daf
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9000000000-f966b80b7d4c362bc68c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9000000000-63358c26586310bea580
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9000000000-a32af1e0d91746768420
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9000000000-dd95e84227d5a66138e1
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03di-1900000000-23c7df4b4c62d2dce32a
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-9000000000-3b1f68acf7d86b277194
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-9000000000-bc675bae86e11cbc3f46
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-9000000000-6271407e28e1fc55d1a5
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00kf-9000000000-845489f9fa893fc89498
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9000000000-160af36d11827e420769
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9200000000-90edafcb4957e4893300
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9200000000-1ff0c747d1e83d9eac05
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9000000000-ed7aaa01b064b00e08a7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9000000000-5ad802258fbfb5471d37

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylmethylamines
Direct Parent
Phenylmethylamines
Alternative Parents
Benzylamines / Aralkylamines / Trialkylamines / Acetylides / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenylmethylamine / Benzylamine / Aralkylamine / Tertiary aliphatic amine / Tertiary amine / Acetylide / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
aromatic amine (CHEBI:7930) / a small molecule (CPD-13898)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Chrisp P, Mammen GJ, Sorkin EM: Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging. 1991 May;1(3):228-48. [PubMed:1794016]
  2. Heinonen EH, Myllyla V: Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf. 1998 Jul;19(1):11-22. [PubMed:9673855]
  3. Authors unspecified: Selegiline: a second look. Six years later: too risky in Parkinson's disease. Prescrire Int. 2002 Aug;11(60):108-11. [PubMed:12199263]
  4. Macleod AD, Counsell CE, Ives N, Stowe R: Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898. [PubMed:16034956]
  5. Magyar K, Tothfalusi L: Pharmacokinetic aspects of deprenyl effects. Pol J Pharmacol Pharm. 1984 Jul-Aug;36(4):373-84. [PubMed:6441926]
  6. Heinonen EH, Anttila MI, Lammintausta RA: Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):742-9. [PubMed:7995016]
  7. Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309. [PubMed:11978145]
  8. Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006 May;11(5):363-75. [PubMed:16641841]
  9. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22. [PubMed:17715422]
  10. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583]
  11. Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5. [PubMed:17823646]
  12. Villeneuve C, Caudrillier A, Ordener C, Pizzinat N, Parini A, Mialet-Perez J: Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8. doi: 10.1152/ajpheart.00345.2009. Epub 2009 Jun 19. [PubMed:19542488]
  13. Murphy DL, Karoum F, Pickar D, Cohen RM, Lipper S, Mellow AM, Tariot PN, Sunderland T: Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). J Neural Transm Suppl. 1998;52:39-48. [PubMed:9564606]
  14. Fuentes JA, Ordaz A, Neff NH: Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur J Pharmacol. 1979 Jul 15;57(1):21-7. [PubMed:477738]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006 May;11(5):363-75. [PubMed:16641841]
  2. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22. [PubMed:17715422]
  3. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583]
  4. Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5. [PubMed:17823646]
  5. Murphy DL, Karoum F, Pickar D, Cohen RM, Lipper S, Mellow AM, Tariot PN, Sunderland T: Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). J Neural Transm Suppl. 1998;52:39-48. [PubMed:9564606]
  6. Fuentes JA, Ordaz A, Neff NH: Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur J Pharmacol. 1979 Jul 15;57(1):21-7. [PubMed:477738]

Drug created on August 29, 2007 15:04 / Updated on November 09, 2017 03:02